Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2008 Jun 19;358(25):2664-5.
doi: 10.1056/NEJMp0803663.

Cancer immunotherapy--the endgame begins

Louis M Weiner  1
Affiliations
Comment

Cancer immunotherapy--the endgame begins

Louis M Weiner. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tumors evade or defeat the host tumor response to obtain a host-specific selective survival advantage.
See this image and copyright information in PMC

Comment in

  • Cancer immunotherapy.
    Prestwich R, Vile R, Melcher A. Prestwich R, et al. N Engl J Med. 2008 Sep 4;359(10):1072; author reply 1073. N Engl J Med. 2008. PMID: 18777615 No abstract available.

Comment on

  • Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
    Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Hunder NN, et al. N Engl J Med. 2008 Jun 19;358(25):2698-703. doi: 10.1056/NEJMoa0800251. N Engl J Med. 2008. PMID: 18565862 Free PMC article.
  • Cancer immunology.
    Finn OJ. Finn OJ. N Engl J Med. 2008 Jun 19;358(25):2704-15. doi: 10.1056/NEJMra072739. N Engl J Med. 2008. PMID: 18565863 Review. No abstract available.

References

    1. Durant JR. Immunotherapy of cancer: the end of the beginning? N Engl J Med. 1987 Apr 9;316(15):939–941. PMID: 3493434. - PubMed
    1. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. PMID: 3493432. Blood. 1993 Oct 15;82(8):2310-8. - PubMed
    1. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993 Oct 15;82(8):2310–2318. - PubMed
    1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001 Apr 26;410(6832):1107–1111. PMID:11323675. - PubMed
    1. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006 Oct 6;314(5796):126–129. Epub 2006 Aug 31. PMID: 16946036. - PMC - PubMed